The GPR171 pathway in cancer immunotherapy
The GPR171 pathway in cancer immunotherapy
批准号:
10635418
负责人:
Yuwen Zhu
金额:
$35.57万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-25 至 2028-03-31
关键词:
AntibodiesAntigensAntitumor ResponseAnxietyCAR T cell therapyCTLA4 geneCancer PatientCannabidiolCannabinoidsCannabisCell physiologyCellular Metabolic ProcessClinicClinicalDataDatabasesExhibitsFamilyFoodFunctional disorderG-Protein-Coupled ReceptorsGeneticGenetic TranscriptionGenus HippocampusGoalsHumanHyperactivityImmune EvasionImmunityImmunosuppressionImmunotherapyKnowledgeLigandsMalignant NeoplasmsMediatingMetabolicModelingMolecularMusNeuropeptidesOutcomePD-1 inhibitorsPD-1/PD-L1Pathway interactionsPatientsPeptide VaccinesPositioning AttributeProteinsPublicationsReportingResearchResearch Project GrantsRoleSignal PathwaySignal TransductionT cell differentiationT cell responseT-Cell ProliferationT-Cell ReceptorT-LymphocyteTestingTherapeuticTimeTranscriptTumor ImmunityTumor SuppressionUp-Regulationanandamideantagonistanti-PD1 therapyanti-canceranti-tumor immune responsecancer immunotherapycancer therapycancer typecannabinoid receptorclinically relevanteffector T cellefficacy evaluationgenetic signaturehumanized mouseimmune cell checkpointsimmune checkpointimmune checkpoint blockersimprovedmarijuana usemelanomamouse modelneoplasm immunotherapyneoplastic cellnew therapeutic targetnovelprotein expressionreceptorreceptor-mediated signalingresistance mechanismresponsesingle-cell RNA sequencingtumortumor microenvironmentuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Scientific Abstract of proposed research project
Immune checkpoint blocker therapy has revolutionized our clinical approach in cancer therapy. However, the
overall response rate still has room for improvement and varies greatly in different cancer types. The
redundant but unique role of immune checkpoints in T cell immunity propels us to further study the role of
novel immune checkpoints in cancer therapy. The BigLEN/GPR171 interaction is a newly identified GPCR
pathway that has been reported to regulate food uptake and anxiety. Though GPR171 is commonly used as a
T cell signature gene, its potential role in T cell immunity has not been explored. Our recent studies have
implicated that the GPR171/BigLEN axis is a new T cell checkpoint pathway that can be modulated for cancer
immunotherapy. We found that GPR171 is transcribed in T cells and its protein expression is induced upon
antigen stimulation. The neuropeptide ligand BigLEN interacts with GPR171 to suppress T cell receptor-
mediated signaling pathways and to inhibit T cell proliferation. Loss of GPR171 in T cells leads to hyperactivity
to antigen stimulation and GPR171-deficient mice exhibit enhanced antitumor immunity. Blockade of GPR171
signaling by an antagonist promotes antitumor T cell immunity in various mouse tumor models. Our preliminary
data further implicate that GPR171 can be an inhibitory receptor on T cell for cannabinoids. In the proposed
study, we will dissect the role of GPR171 ligands in GPR171-mediated antitumor suppression. We will further
determine the molecular mechanisms that GPR171 signaling inhibits anticancer T cell response. The approach
of GPR171 blockade for cancer therapy will be tested in clinical tumor models, including chimeric antigen
receptor T-cell therapy and humanized mouse model together with anti- PD-1 therapy. By the completion of
these studies, our discovery that GPR171 is a receptor for cannabinoids will help to better understand the
impact of cannabis usage in cancer treatment, more importantly, provide new strategies of cancer
immunotherapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Melanoma Immunotherapy with GPR182 blockade
-
批准号:10585749
-
项目类别:
-
资助金额:$35.57万
-
财政年份:2023
-
负责人:Yuwen Zhu
-
依托单位:
The CD93 pathway and melanoma therapy
-
批准号:10534230
-
项目类别:
-
资助金额:$34.86万
-
财政年份:2021
-
负责人:Yuwen Zhu
-
依托单位:
The CD93 pathway and melanoma therapy
-
批准号:10364508
-
项目类别:
-
资助金额:$35.57万
-
财政年份:2021
-
负责人:Yuwen Zhu
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: